P/E ratio for Palatin Technologies (PTN)

P/E ratio history for Palatin Technologies from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
MediciNova MNOV	-6.06	593.46%	🇺🇸 USA
GlycoMimetics GLYC	-0.3019	-65.45%	🇺🇸 USA
Neurocrine Biosciences NBIX	34.7	-4,068.24%	🇺🇸 USA
ANI Pharmaceuticals ANIP	47.4	-5,521.83%	🇺🇸 USA
Ligand Pharmaceuticals LGND	81.1	-9,385.33%	🇺🇸 USA
Dicerna Pharmaceuticals DRNA	N/A	N/A	🇺🇸 USA
Johnson & Johnson JNJ	20.0	-2,392.41%	🇺🇸 USA
Ardelyx ARDX	-26.3	2,907.59%	🇺🇸 USA
AstraZeneca AZN	29.9	-3,516.14%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.